Ikaro S. Breder
Campinas, SP 13084971, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial.
Journal: Cardiovascular diabetology
Published: November 05, 2025
LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial.
Journal: Atherosclerosis
Published: August 19, 2025
Obesity-Induced Metabolic Priming Exacerbates SARS-CoV-2 Inflammation.
Journal: Immunology
Published: January 07, 2025
Dapagliflozin reduces the white coat effect on systolic blood pressure of patients with type 2 diabetes: a post-hoc analysis from the ADDENDA-BHS 2 trial.
Journal: Current medical research and opinion
Published: December 20, 2024
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial.
Journal: International journal of molecular sciences
Published: February 16, 2024
Insights from a Wolfram syndrome cohort: clinical and molecular findings from a specialized diabetes reference center.
Journal: Archives of endocrinology and metabolism
Published: February 02, 2024
Health literacy and diabetic retinopathy.
Journal: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica
Published: June 29, 2023
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
Journal: Cardiovascular diabetology
Published: June 29, 2022
Rationale and design of the Brazilian diabetes study: a prospective cohort of type 2 diabetes.
Journal: Current medical research and opinion
Published: February 17, 2022
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis.
Journal: Diagnostics (Basel, Switzerland)
Published: February 07, 2022
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Journal: Diabetes & metabolism
Published: October 19, 2021
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.
Journal: Diabetes & metabolism
Published: May 10, 2021
Last Updated: 09/26/2026